Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.35 |
| ▸ | ACP1 | P24666 | 3/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5645241 | 0.94 | KMT2A (0.36) | AKR1B1KMT2APTPN1ACP1HDAC6 | |
| SCHEMBL5646331 | 0.91 | PTPN1 (0.34) | AKR1B1KMT2APTPN1ACP1HDAC6 | |
| SCHEMBL5653212 | 0.90 | CYP1A2 (0.34) | AKR1B1KMT2APTPN1ACP1HDAC6 | |
| SCHEMBL5647961 | 0.89 | HTR1A (0.33) | AKR1B1KMT2APTPN1ACP1HDAC6 | |
| SCHEMBL5647793 | 0.89 | OPRM1 (0.34) | KMT2APTPN1ACP1HDAC6CTRB1 | |
| SCHEMBL5649247 | 0.89 | PTPN1 (0.44) | KMT2APTPN1ACP1HDAC6CTRB1 | |
| SCHEMBL5650645 | 0.88 | HTR1A (0.35) | KMT2APTPN1ACP1MEN1CYP3A4 | |
| SCHEMBL5646512 | 0.88 | HTR1A (0.35) | KMT2APTPN1ACP1MEN1CYP3A4 | |
| SCHEMBL5650011 | 0.88 | PTPN1 (0.33) | KMT2APTPN1ACP1HDAC6CTRB1 | |
| SCHEMBL5648086 | 0.88 | CTRB1 (0.40) | KMT2APTPN1ACP1HDAC6CTRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199146-B2 | Imidazolidinedione analogs useful as anticoagulants and antithrombotics | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-04-03 | — | — | US | disclosed |
| US-20060142363-A1 | Imidazolidinedione analogs useful as anticoagulants and antithrombotics | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-29 | — | — | US | disclosed |
| US-7053112-B2 | Imidazolidinedione analogs useful as anticoagulants and antithrombotics | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-30 | — | — | US | disclosed |
| US-20040122073-A1 | Imidazolidinedione analogs useful as anticoagulants and antihrombotics | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122073-A1 | Imidazolidinedione analogs useful as anticoagulants and antihrombotics | SERPINC1, F2, BDKRB1 | AKR1B1 914/4885KMT2A 3162/4885PTPN1 1843/4885 |
| US-20060142363-A1 | Imidazolidinedione analogs useful as anticoagulants and antithrombotics | SERPINC1, F2, BDKRB1 | AKR1B1 627/4885KMT2A 3939/4885PTPN1 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.